Lymph node-only metastatic gastric/gastroesophageal junction cancer and efficacy of immunotherapy
- PMID: 32424650
- DOI: 10.1007/s10120-020-01084-2
Lymph node-only metastatic gastric/gastroesophageal junction cancer and efficacy of immunotherapy
Comment on
-
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.Gastric Cancer. 2020 May;23(3):510-519. doi: 10.1007/s10120-019-01034-7. Epub 2019 Dec 20. Gastric Cancer. 2020. PMID: 31863227 Free PMC article. Clinical Trial.
Similar articles
-
[A Case of Long Survival with Hilar Lymph Node Metastasis from Gastric Cancer Successfully Treated with Nivolumab Immunotherapy].Gan To Kagaku Ryoho. 2019 Dec;46(13):2315-2317. Gan To Kagaku Ryoho. 2019. PMID: 32156916 Japanese.
-
Ratio of metastatic to examined lymph nodes, a helpful staging system and independent prognostic factor of esophagogastric junction cancer.PLoS One. 2013 Aug 19;8(8):e73238. doi: 10.1371/journal.pone.0073238. eCollection 2013. PLoS One. 2013. PMID: 23977381 Free PMC article.
-
The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.BMC Cancer. 2017 Dec 28;17(1):893. doi: 10.1186/s12885-017-3918-9. BMC Cancer. 2017. PMID: 29282088 Free PMC article. Clinical Trial.
-
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.J Clin Oncol. 2023 Mar 1;41(7):1470-1491. doi: 10.1200/JCO.22.02331. Epub 2023 Jan 5. J Clin Oncol. 2023. PMID: 36603169
-
Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.Eur J Cancer. 2022 Nov;176:13-29. doi: 10.1016/j.ejca.2022.08.023. Epub 2022 Sep 29. Eur J Cancer. 2022. PMID: 36183651 Review.
Cited by
-
Present situation and prospect of immunotherapy for unresectable locally advanced esophageal cancer during peri-radiotherapy.World J Gastrointest Oncol. 2024 Jan 15;16(1):1-7. doi: 10.4251/wjgo.v16.i1.1. World J Gastrointest Oncol. 2024. PMID: 38292836 Free PMC article.
-
Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma.Cancer Med. 2023 Aug;12(16):16837-16845. doi: 10.1002/cam4.6306. Epub 2023 Jul 5. Cancer Med. 2023. PMID: 37403728 Free PMC article.
References
-
- Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Kang YK, Boku N. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer. 2020;23(3):510–9. https://doi.org/10.1007/s10120-019-01034-7 Epub 2019 Dec 20 PubMed PMID: 31863227. - DOI - PubMed
-
- Schmid S, Diem S, Li Q, et al. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). Cancer Immunol Immunother. 2018;67(12):1825–32. https://doi.org/10.1007/s00262-018-2239-4 . - DOI - PubMed
-
- Kashima S, Tanabe H, Tanino M, et al. Lymph node metastasis from gastroesophageal cancer successfully treated by nivolumab: a case report of a young patient. Front Oncol. 2019;9:1375. https://doi.org/10.3389/fonc.2019.01375 Published 2019 Dec 16. - DOI - PubMed - PMC
-
- Morelli C et al. (2020) Gastric immune prognostic index (GIPI) in metastatic (m) gastro-oesophageal junction (GOJ)/gastric cancer (GC) patients (pts) treated with PD-1/PD-L1 immune checkpoint inhibitors (ICIs). J Clin Oncol 38(4_suppl):417–417. DOI: 10.1200/JCO.2020.38.4_suppl.417
-
- Mangiola S, Hong MK, Cmero M, et al. Comparing nodal versus bony metastatic spread using tumour phylogenies. Sci Rep. 2016;6:33918. https://doi.org/10.1038/srep33918 Published 2016 Sep 22. - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical